ContributorsPublishersAdvertisers

Anlotinib Plus Irinotecan or Docetaxel Shows Promising Efficacy in SCLC

cancernetwork.com
 2021-10-11

Cover picture for the articlePatients with small cell lung cancer who failed first-line treatment within 6 months were examined for efficacy of anlotinib plus chemotherapy in a phase 2 trial whose results were presented at the 2021 ESMO Congress. Patients with small cell lung cancer (SCLC) for whom first-line therapy failed within 6...

www.cancernetwork.com

Comments / 0

Comments / 0